Legal Action Launched by Ario Khoshbin Over CEO Dismissal from Prollenium Medical Technologies
Ario Khoshbin, the founder of Prollenium Medical Technologies Inc., has recently filed a lawsuit in the Ontario Superior Court of Justice, alleging that his removal as CEO was not only unjust but also a breach of trust and contractual obligations by the company and its stakeholders. The lawsuit cites defendants including ArchiMed SAS, a European private equity firm that acquired a majority stake in Prollenium in 2021.
Since its inception in 2002, Prollenium has evolved into a leading global player in the aesthetics market. Khoshbin has been instrumental in establishing the company as the only North American manufacturer of hyaluronic acid-based dermal fillers, providing their products in over 80 countries. In his complaint, Ario claims that the actions of ArchiMed since acquiring a significant share have not only marginalized minority shareholders like himself but have also prioritized short-term financial metrics over long-term innovation and sustainability—the very principles that had underpinned Prollenium’s success.
Khoshbin's legal documents assert that after the acquisition, his role was systematically diminished, leading to his removal from critical business decisions. He argues that his ousting on April 4, 2025, was conducted in a manner that violated both legal and ethical norms, contradicting previous assurances from company officials.
The lawsuit further indicates that Khoshbin was not given opportunities for a fair performance review before his termination and asserts that he had been prepared to ensure a smooth transition in management. Evidence is presented that suggests a premeditated plan by ArchiMed to appoint Walter Geiger—currently an operating partner at ArchiMed—without obtaining the necessary work permits required in Canada at the time of his appointment.
Post-termination, Khoshbin has resigned from the Board of Directors of Panacea Holdings but continues to hold a significant indirect ownership stake in Prollenium. Speaking on his tenure at the company, Khoshbin stated, "Building Prollenium has been the defining journey of my professional life. Even though I had to step away from the CEO position unexpectedly, my dedication to the legacy and future of the company remains steadfast."
The lawsuit requests several forms of relief, including a fair market buyout of Khoshbin's shares, as well as compensation for wrongful dismissal and reputational damage. It is important to note that these assertions have yet to be validated in a court of law and remain allegations at this stage of litigation.
In the ever-changing landscape of the aesthetics industry, this legal drama highlights the complexities and often turbulent nature of corporate governance, especially in firms that experience rapid growth and significant changes in ownership structure. As the case unfolds, many industry stakeholders and observers will be eager to see the outcomes of this litigation. Will it pave the way for greater protection of minority shareholders in similar circumstances, or will it underscore the challenges posed by private equity involvement in corporate governance? Only time will tell.
Since its inception in 2002, Prollenium has evolved into a leading global player in the aesthetics market. Khoshbin has been instrumental in establishing the company as the only North American manufacturer of hyaluronic acid-based dermal fillers, providing their products in over 80 countries. In his complaint, Ario claims that the actions of ArchiMed since acquiring a significant share have not only marginalized minority shareholders like himself but have also prioritized short-term financial metrics over long-term innovation and sustainability—the very principles that had underpinned Prollenium’s success.
Khoshbin's legal documents assert that after the acquisition, his role was systematically diminished, leading to his removal from critical business decisions. He argues that his ousting on April 4, 2025, was conducted in a manner that violated both legal and ethical norms, contradicting previous assurances from company officials.
The lawsuit further indicates that Khoshbin was not given opportunities for a fair performance review before his termination and asserts that he had been prepared to ensure a smooth transition in management. Evidence is presented that suggests a premeditated plan by ArchiMed to appoint Walter Geiger—currently an operating partner at ArchiMed—without obtaining the necessary work permits required in Canada at the time of his appointment.
Post-termination, Khoshbin has resigned from the Board of Directors of Panacea Holdings but continues to hold a significant indirect ownership stake in Prollenium. Speaking on his tenure at the company, Khoshbin stated, "Building Prollenium has been the defining journey of my professional life. Even though I had to step away from the CEO position unexpectedly, my dedication to the legacy and future of the company remains steadfast."
The lawsuit requests several forms of relief, including a fair market buyout of Khoshbin's shares, as well as compensation for wrongful dismissal and reputational damage. It is important to note that these assertions have yet to be validated in a court of law and remain allegations at this stage of litigation.
In the ever-changing landscape of the aesthetics industry, this legal drama highlights the complexities and often turbulent nature of corporate governance, especially in firms that experience rapid growth and significant changes in ownership structure. As the case unfolds, many industry stakeholders and observers will be eager to see the outcomes of this litigation. Will it pave the way for greater protection of minority shareholders in similar circumstances, or will it underscore the challenges posed by private equity involvement in corporate governance? Only time will tell.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.